PT - JOURNAL ARTICLE AU - Wei Zhou AU - Masahiro Kanai AU - Kuan-Han H Wu AU - Rasheed Humaira AU - Kristin Tsuo AU - Jibril B Hirbo AU - Ying Wang AU - Arjun Bhattacharya AU - Huiling Zhao AU - Shinichi Namba AU - Ida Surakka AU - Brooke N Wolford AU - Valeria Lo Faro AU - Esteban A Lopera-Maya AU - Kristi Läll AU - Marie-Julie Favé AU - Sinéad B Chapman AU - Juha Karjalainen AU - Mitja Kurki AU - Maasha Mutaamba AU - Ben M Brumpton AU - Sameer Chavan AU - Tzu-Ting Chen AU - Michelle Daya AU - Yi Ding AU - Yen-Chen A Feng AU - Christopher R Gignoux AU - Sarah E Graham AU - Whitney E Hornsby AU - Nathan Ingold AU - Ruth Johnson AU - Triin Laisk AU - Kuang Lin AU - Jun Lv AU - Iona Y Millwood AU - Priit Palta AU - Anita Pandit AU - Michael Preuss AU - Unnur Thorsteinsdottir AU - Jasmina Uzunovic AU - Matthew Zawistowski AU - Xue Zhong AU - Archie Campbell AU - Kristy Crooks AU - Geertruida h De Bock AU - Nicholas J Douville AU - Sarah Finer AU - Lars G Fritsche AU - Christopher J Griffiths AU - Yu Guo AU - Karen A Hunt AU - Takahiro Konuma AU - Riccardo E Marioni AU - Jansonius Nomdo AU - Snehal Patil AU - Nicholas Rafaels AU - Anne Richmond AU - Jonathan A Shortt AU - Peter Straub AU - Ran Tao AU - Brett Vanderwerff AU - Kathleen C Barnes AU - Marike Boezen AU - Zhengming Chen AU - Chia-Yen Chen AU - Judy Cho AU - George Davey Smith AU - Hilary K Finucane AU - Lude Franke AU - Eric Gamazon AU - Andrea Ganna AU - Tom R Gaunt AU - Tian Ge AU - Hailiang Huang AU - Jennifer Huffman AU - Clara Lajonchere AU - Matthew H Law AU - Liming Li AU - Cecilia M Lindgren AU - Ruth JF Loos AU - Stuart MacGregor AU - Koichi Matsuda AU - Catherine M Olsen AU - David J Porteous AU - Jordan A Shavit AU - Harold Snieder AU - Richard C Trembath AU - Judith M Vonk AU - David Whiteman AU - Stephen J Wicks AU - Cisca Wijmenga AU - John Wright AU - Jie Zheng AU - Xiang Zhou AU - Philip Awadalla AU - Michael Boehnke AU - Nancy J Cox AU - Daniel H Geschwind AU - Caroline Hayward AU - Kristian Hveem AU - Eimear E Kenny AU - Yen-Feng Lin AU - Reedik Mägi AU - Hilary C Martin AU - Sarah E Medland AU - Yukinori Okada AU - Aarno V Palotie AU - Bogdan Pasaniuc AU - Serena Sanna AU - Jordan W Smoller AU - Kari Stefansson AU - David A van Heel AU - Robin G Walters AU - Sebastian Zoellner AU - Biobank Japan AU - BioMe AU - BioVU AU - Canadian Partnership for Tomorrow AU - China Kadoorie Biobank Collaborative Group AU - Colorado Center for Personalized Medicine AU - deCODE Genetics AU - Estonian Biobank AU - FinnGen AU - Generation Scotland AU - Genes & Health AU - LifeLines AU - Mass General Brigham Biobank AU - Michigan Genomics Initiative AU - QIMR Berghofer Biobank AU - Taiwan Biobank AU - The HUNT Study AU - UCLA ATLAS Community Health Initiative AU - UK Biobank AU - Alicia R Martin AU - Cristen J Willer AU - Mark J Daly AU - Benjamin M Neale TI - Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases AID - 10.1101/2021.11.19.21266436 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.19.21266436 4099 - http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266436.short 4100 - http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266436.full AB - Biobanks are being established across the world to understand the genetic, environmental, and epidemiological basis of human diseases with the goal of better prevention and treatments. Genome-wide association studies (GWAS) have been very successful at mapping genomic loci for a wide range of human diseases and traits, but in general, lack appropriate representation of diverse ancestries - with most biobanks and preceding GWAS studies composed of individuals of European ancestries. Here, we introduce the Global Biobank Meta-analysis Initiative (GBMI) -- a collaborative network of 19 biobanks from 4 continents representing more than 2.1 million consented individuals with genetic data linked to electronic health records. GBMI meta-analyzes summary statistics from GWAS generated using harmonized genotypes and phenotypes from member biobanks. GBMI brings together results from GWAS analysis across 6 main ancestry groups: approximately 33,000 of African ancestry either from Africa or from admixed-ancestry diaspora (AFR), 18,000 admixed American (AMR), 31,000 Central and South Asian (CSA), 341,000 East Asian (EAS), 1.4 million European (EUR), and 1,600 Middle Eastern (MID) individuals. In this flagship project, we generated GWASs from across 14 exemplar diseases and endpoints, including both common and less prevalent diseases that were previously understudied. Using the genetic association results, we validate that GWASs conducted in biobanks worldwide can be successfully integrated despite heterogeneity in case definitions, recruitment strategies, and baseline characteristics between biobanks. We demonstrate the value of this collaborative effort to improve GWAS power for diseases, increase representation, benefit understudied diseases, and improve risk prediction while also enabling the nomination of disease genes and drug candidates by incorporating gene and protein expression data and providing insight into the underlying biology of the studied traits.Competing Interest StatementM.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. The spouse of C.J.W works at Regeneron Pharmaceuticals. C.Y.C. is employed by Biogen. C.R.G. owns stock in 23andMe, Inc. T.R.G. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. E.E.K. has received speaker fees from Regeneron, Illumina, and 23&Me, and is a member of the advisory board for Galateo Bio. R.E.M. has received speaker fees from Illumina and is a scientific advisor to the Epigenetic Clock Development Foundation. G.D.S has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. K.S. and U.T. are employed by deCODE Genetics/Amgen inc. J.Z. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization.Funding StatementPlease refer to Supplementary Note for information regarding individual studies involved in the Global Biobank Meta-analysis Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Please refer to Supplementary Note for information regarding individual studies involved in the Global Biobank Meta-analysis Initiative.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe all-biobank meta-analysis results and plots for the 14 endpoints (including both ancestry-specific and cross-ancestry meta-analyses and sex stratified meta-analyses) are available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org. Custom scripts used for quality control, meta-analysis and summary of results are available at https://github.com/globalbiobankmeta. The optimized trans-ancestry and single-ancestry polygenic score weights will be deposited within the PGS Catalog (https://www.pgscatalog.org/). https://www.globalbiobankmeta.org/resources